IncobotulinumtoxinA 100 UNT

ApprovedSmall molecule

IncobotulinumtoxinA 100 UNT is one of 32 small molecule programs targeting Lower limb spasticity. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lower Limb SpasticityActive, not recruiting

Thoracic Outlet SyndromeActive, not recruiting

Overactive BladderActive, not recruiting

Lower Limb SpasticityPhase 2

Active, not recruiting

Thoracic Outlet SyndromeApproved

Active, not recruiting

Overactive BladderApproved

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Overactive Bladder

#DrugCompanyPhaseTrials

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

3 2

Neurontin

VViatris Specialty LLC

Phase 3

1 3

Botox

AbbVie

Phase 3

3 4

GSK1358820

GSK

Phase 3

1 5

IncobotulinumtoxinA 100 UNT

UUniversita di Verona

Approved

2 6

Tolterodine PR

Pfizer

Phase 3

5 7

Oxybutynin Chloride

Mylan Pharmaceuticals Inc

Phase 3

3 8

Vesicare

Astellas

Phase 3

2 9

YM178

Astellas

Phase 3

6 10

SPM 907

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overactive Bladder2 trials

Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder

Completed·NNiko Kavcic·Phase 4·NCT06250543·64 enrolled

Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin

Unknown status·UUniversity Of Perugia·Phase 3·NCT03758235·140 enrolled

Thoracic Outlet Syndrome1 trial

Whiplash-induced Thoracic Outlet Syndrome Treated With Botulinum Toxin.

Unknown status·KKing, David, MD·Phase 4·NCT05536570·15 enrolled

Lower limb spasticity1 trial

INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)

Unknown status·UUniversita di Verona·Phase 2·NCT05340439·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for IncobotulinumtoxinA 100 UNT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IncobotulinumtoxinA 100 UNT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IncobotulinumtoxinA 100 UNT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universita di Verona company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversita di Verona

IncobotulinumtoxinA 100 UNT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Overactive Bladder2 trials

Thoracic Outlet Syndrome1 trial

Lower limb spasticity1 trial

References

Drug Info

Quick Facts

Related News